Prasugrel(pra’ soo grel)
Effient
PREGNANCY CATEGORY B
Drug Class
Platelet inhibitor
Therapeutic Actions
Inhibits platelet activation and aggregation by irreversibly binding to the P2Y12 class of ADP receptors on platelets.
Indications
To reduce the risk of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention, including patients with unstable angina or non-ST-elevation MI and patients with ST-elevation MI who will be managed with primary or delayed percutaneous coronary intervention
Contraindications and Cautions
Contraindicated with hypersensitivity to components of drug, active pathologic bleeding, history of TIA or stroke, patients likely to undergo CABG surgery.
Use cautiously with age 75 yr and older, body weight less than 60 kg, bleeding tendency, use of drugs that increase risk of bleeding, pregnancy, lactation.
Available Forms
Tablets—5, 10 mg
Dosages
Adults
Loading dose: 60 mg PO as single dose, then 10 mg/day PO without regard to food; use 5 mg/day in patients weighing less than 60 kg. Patient should also be receiving aspirin (75–325 mg/day).
Pediatric patients
Safety and efficacy not established.
Geriatric patients
Not recommended in patients 75 yr or older except in high-risk situations in which benefit out-weighs risk.
Pharmacokinetics
|
Metabolism: Hepatic; T1/2: 2–15 hr
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
